The earnings call highlighted significant progress in advancing key drug candidates, particularly ABCL635 and ABCL575, alongside a strong liquidity position to support ongoing and future programs. However, the call also noted a decline in revenue and increased net loss, with some development programs paused. The sentiment reflects a balance between ongoing challenges and strategic advancements.

Company Guidance -

Q3 2025

During the first quarter of 2025, AbCellera focused on advancing their key priorities, including initiating Phase 1 clinical trials for ABCL635 and ABCL575, which are set to start in Q3 of 2025, with key readouts expected by mid-2026. ABCL635, a first-in-class therapeutic antibody targeting the neurokinin 3 receptor (NK3R) for non-hormonal treatment of vasomotor symptoms associated with menopause, represents a significant market opportunity, valued at over $2 billion annually. Approximately 30% of women experience these symptoms, with more than half seeking treatment. AbCellera aims to differentiate ABCL635 with a monthly injectable format preferred by over 50% of surveyed women, compared to daily oral treatments. Financially, the company maintained a strong liquidity position with $630 million in cash and equivalents and $180 million in committed government funding, despite a net loss of $46 million for the quarter, driven by R&D expenses of $43 million. The company's ongoing investments focus on internal programs and completing clinical manufacturing capabilities, which are set to come online by the end of 2025.

Introduction of ABCL635

ABCL635 is a potential first-in-class therapeutic antibody for non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. This represents a significant market opportunity with a potential for over $2 billion in annual sales.

Strong Liquidity Position

AbCellera continues to be in a strong liquidity position with approximately $630 million in cash and equivalents and roughly $180 million in available committed government funding.

Advancement of ABCL575

ABCL575 is on track with CTA filing in Q2 and anticipated start of Phase 1 clinical trials in Q3. Preclinical data will be presented at the Society for Investigative Dermatology's Annual Meeting.

Platform and Pipeline Development

AbCellera is transitioning from a platform company to a clinical-stage biotech with a portfolio of more than 20 internal and co-development programs. Investments in clinical manufacturing capabilities are nearing completion.

AbCellera Biologics (ABCL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABCL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.14 / -	-0.17	―	―	―
Aug 07, 2025	2025 (Q2)	-0.13 / -0.12	-0.13	7.69% (+0.01)
May 08, 2025	2025 (Q1)	-0.14 / -0.15	-0.14	-7.14% (>-0.01)
Feb 27, 2025	2024 (Q4)	-0.13 / -0.12	-0.16	25.00% (+0.04)
Nov 04, 2024	2024 (Q3)	-0.12 / -0.17	-0.1	-70.00% (-0.07)
Aug 06, 2024	2024 (Q2)	-0.12 / -0.13	-0.11	-18.18% (-0.02)
May 07, 2024	2024 (Q1)	-0.13 / -0.14	-0.14	0.00% (0.00)
Feb 20, 2024	2023 (Q4)	-0.12 / -0.16	-0.1	-60.00% (-0.06)
Nov 02, 2023	2023 (Q3)	-0.12 / -0.10	0.08	-225.00% (-0.18)
Aug 03, 2023	2023 (Q2)	-0.13 / -0.11	-0.02	-450.00% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABCL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.24	―	―
May 08, 2025	$2.01	$2.03	+1.00%
Feb 27, 2025	$2.92	$2.58	-11.64%
Nov 04, 2024	$2.89	$2.72	-5.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AbCellera Biologics (ABCL) report earnings?

AbCellera Biologics (ABCL) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is AbCellera Biologics (ABCL) earnings time?

AbCellera Biologics (ABCL) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABCL EPS forecast?

ABCL EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing